Skip to content

Intratracheal Dexmedetomidine Versus Lidocaine in Eye Surgery

The Efficacy and Safety of Intratracheal Dexmedetomidine Versus Lidocaine for Smooth Tracheal Extubation in Patients Undergoing Eye-surgery.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05291221
Enrollment
120
Registered
2022-03-22
Start date
2021-02-22
Completion date
2022-07-30
Last updated
2023-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Complications

Keywords

intratracheal, dexmedetomidine, eye-surgery, lidocaine

Brief summary

Cough during emergence from general anesthesia is considered a critical event as it may lead to surgical bleeding laryngospasm hemodynamic instability and could be life-threatening in patients who are at risk of complications related to increases in intracranial or intraocular pressure. Lidocaine administration has been widely used for reducing cough during extubation due to its simplicity and lack of serious adverse effects; There are two major routes for lidocaine administration systemic intravenous injection and local direct application on the laryngeal inlets such as spraying lidocaine on the supraglottic and subglottic regions or applying lidocaine jelly or sprayed. Dexmedetomidine is a potent alpha 2 selective adrenoceptor agonist and the most characteristic features include sympatholytic sedation analgesia and lack of respiratory depression. The aim of this study is to compare the effect of intratracheal dexmedetomidine and lidocaine on cough reflex in cataract surgery.

Detailed description

The patients were randomly allocated into three groups each containing (40) patient. Group D received (0.5 μg/kg) of dexmedetomidine diluted and completed to 5 ml saline, Group L received (5ml) 2% of lidocaine and Group C received 5ml saline. The drugs were sprayed down the intratracheal tube of patients. The following variables: Hemodynamic parameters HR, MAP, and SaO2 values in different times, preoperative IOP, cough, steward recovery score (SRS), detection of awareness and extubation time, the incidence of complications due to increasing IOP and surgeon satisfaction

Interventions

DRUGintratracheal saline

At the end of the operation by 15min, 5ml of 0.9% normal saline was sprayed down the intratracheal tube of patients

At the end of the operation by 15min, Dexmedetomidine (0.5µg/kg, diluted in 5mL saline in a medical spray bottle) was sprayed down the intratracheal tube of patients

DRUGintratracheal Lidocaine

At the end of the operation by 15min, (5ml) 2% of lidocaine was sprayed down the intratracheal tube of patients.

Sponsors

Minia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
16 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Adult patients aged from 18 to 60 years old * ASA I or II class * Undergo elective intraocular surgery * Under general anesthesia.

Exclusion criteria

* Renal impairment * Cardiorespiratory abnormalities * Bronchial asthma COPD * Restrictive lung diseases * Liver failure * Allergy to drugs will be used * Patient refuse * Pregnancy-lactation * Significant obesity

Design outcomes

Primary

MeasureTime frameDescription
Cough reflex.from time of awareness to 5 minute after extubationTo evaluate efficacy and safety of both dexmedetomidine and lidocaine on Cough: from time of awareness to 5 minute after extubation 0= no cough 1. minimal Cough (single) 2. moderate cough\<= 5S 3. severe cough \>=5S (bucking)

Secondary

MeasureTime frameDescription
mean arterial blood pressurebefore anesthesia up to 30 minute after extubationPerioperative mean arterial blood pressure values were recorded
heart ratebefore anesthesia up to 30 minute after extubationPerioperative heart rate values were recorded

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026